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cThe numerous advances in our understanding of
ransplantation biology combined with enhancements
n supportive care have substantially improved the
ealth of our patients. Transplant-related morbidity
as progressively declined over the last 30 years, and
his can be at least in part measured by our ability to
rovide stem cell transplantation to an aging popula-
ion and by our ﬂedgling ability to cross histocompat-
bility barriers. However, a persistently frustrating
imitation in transplantation medicine is delayed, in-
dequate, or incomplete reconstitution of the immune
ystem. Patients die of opportunistic infections despite
ell-controlled graft-versus-host disease (GVHD)
nd eradication of the underlying disease. Although
VHD control, improvements in antibiotic spectra,
nd circumspection in the use of immunosuppressants
ave helped, too many patients still die of infections
ecause of insufﬁcient immunologic recovery.
Immunologic recovery and GVHD are intrinsi-
ally linked. It is helpful to think of acute GVHD as an
nﬂammatory disorder in which T cells from the do-
or behave appropriately in the context in which they
nd themselves. In other words, the donor’s T cells
ecognize minor histocompatibility antigens in the
etting of upregulated adhesion molecules, inﬂamma-
ory cytokines, and damaged epithelia. Thus, the T
ell’s view of the world is that the host is seriously
nfected, and its job is to respond to this infection by
nitiating and sustaining an effective immune re-
ponse. Of course, the problem is that the effective
mmune response is directed against minor histocom-
atibility differences rather than microbial proteins.
his response is maladaptive from the perspective of a
ransplant clinician. We want the T cells to identify
iral, bacterial, and fungal products in the context of
ajor histocompatibility complex but not minor his-ocompatibility antigens per se. The T cell may not be t
B & M Tuite so obliging; therefore, we are obligated to limit
-cell numbers and paralyze T-cell function. The
onsequences of this strategy are self-evident. One
annot control GVHD without increasing susceptibil-
ty to infection—the 2 entities go hand in hand. This
s why we often have patients who die of severe op-
ortunistic infections after we have induced a “remis-
ion” with our therapy for acute GVHD. We cannot
electively control T-cell function—at least, not yet.
Clinically, we approach transplantation-related im-
une incompetence in stages [1,2] (Table 1). Initially the
atient is myelosuppressed, and the principal risks are
ram-positive and gram-negative bacteria, herpes sim-
lex virus, and candida infection (to name a few). This
eﬂects a failure of innate immunity. Poor granulocyte
nd monocyte function occurs in the setting of mucosal
njury from the conditioning regimen. Myeloid recon-
titution is relatively straightforward and has been facil-
tated by hematopoietic growth factors and stimulated
eripheral blood stem cell products. After myeloid re-
overy, there is a transition period in which there is a
mall amount of passively transferred T-cell function
rom the graft. It was hoped that the larger T-cell num-
ers transferred with a peripheral blood stem cell prod-
ct would provide better initial T-cell function, but such
beneﬁt has yet to be convincingly demonstrated [3,4].
here is a modicum of additional protection from pre-
ormed immunoglobulin, but it is safe to say that there is
inimal immunologic capacity at this stage of transplan-
ation. This failure of the adaptive immune system trans-
ates into susceptibility to virus reactivation (eg, cyto-
egalovirus and varicella-zoster virus), continued
usceptibility to fungal disease, and inability to respond
o less obvious risks such as respiratory syncytial virus,
arainﬂuenza, and other respiratory pathogens. Vac-
ination studies have clearly demonstrated incompe-
ence of both cellular and humoral immunity [5,6]. In
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4he absence of GVHD and in association with the
apering of immunosuppressants, we expect slow re-
onstitution of NK cells, T cells, and eventually B-cell
unction [7]. Much of this component of the problem
ay be attributable to poor thymic function in adults,
s well as limitations in the homeostatic recovery of
- and B-cell numbers. Recovery is slow, but in for-
unate patients there is a restoration of CD4 T-cell
umbers, responsiveness to vaccinations, and reduced
usceptibility to pneumocystis infections and so on in
he months surrounding a year from the transplanta-
ion. Insight into this process can be gleaned from
nalysis of both T-cell receptor reconstitution and
mmunoglobulin recovery [8,9]. Both systems recon-
titute with oligoclonal expansion of the respective
lements. This phenomenon can be clearly observed
y analyzing T-cell receptor V spectrotyping.
learly, active acute or chronic GVHD, prolonged
se of immunosuppressants, mismatched transplanta-
ion, unrelated donor transplantation, and relapse de-
ress the already slow pace of immune reconstitution
10-12]. Furthermore, some data suggest that the use
f ﬁlgrastim after transplantation may increase the risk
f infection by altering the recovery of T-helper cells
12]. It is interesting to note that chronic GVHD may
esult in a speciﬁc inability to synthesize IgG2 and
gG4, which results in prolonged susceptibility to en-
apsulated bacteria [13]. How T-regulatory cells in-
uence immunologic recovery is just now being ana-
yzed [14].
able 1. Relative Immunologic Recovery after Stem Cell Transplantati
Variable
Before
Transplantation 2–3 wk
Innate
Immunity
Adaptive
Immunity
Innate
Immunity
Ada
Imm
yeloablative
transplantation
Pretransplantation
marrow failure 22 ↔ 222 2
Pretransplantation
intensive
chemotherapy ↔ 2 222 22
No pretransplantation
immune failure   222 2
educed-intensity
transplantation
Pretransplantation
marrow failure 22 ↔ 222 2
Pretransplantation
intensive
chemotherapy ↔ 2 2 22
No pretransplantation
immune failure   2 2
Symbols are designed to show the relative competence of the immu
incomplete recovery.We are increasingly recognizing that the prior
4ramework of immunohematologic recovery was too di-
hotomized. Granulocyte and monocyte reconstitution
s critical, but it now seems that the recovery of the
nnate immune system is closely tied to the recovery of
he adaptive immune system. Toll-like receptors are in-
olved in many steps in the generation of inﬂammation
nd help to coordinate both innate and adaptive immu-
ity. Monocytes have a central role in the reticuloendo-
helial system but produce cytokines such as interleukin
IL)–12 and IL-10 that have profound effects on T-cell
unction. Natural killer cells have intrinsic activity as part
f innate immunity, but they also interact with dendritic
ells; they can depress or enhance dendritic cell function
nd thus inﬂuence T-cell function. Ultimately, elucida-
ion of these relationships may provide the insights that
ill allow us to inﬂuence the process. It is unrealistic to
hink that we will be able to intervene in a functionally
omplex system in a way that will be entirely effective. As
uch as we hope that cytokine infusions (eg, IL-7) will
nﬂuence some component of this process, it is likely that
uch agents will affect only a limited component of a
omplex repertoire [15]. It is more likely that combina-
ions of cytokines, cellular therapies, and vaccine strate-
ies will be required to see any effects on immunologic
ecovery. Ultimately, we may need to rethink the entire
pproach to allogeneic transplantation.
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